Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

Semax vs Adamax

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Semax has stronger documented evidence (Russia-Approved + Anecdotal) than Adamax (Anecdotal) while both occupy the nootropic / bdnf-upregulator classes. When clinical-evidence tier is the deciding factor, Semax is the safer pick. Adamax may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Semax

Russia-Approved + Anecdotal

Adamax

Anecdotal

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

Semax Adamax
Class ACTH fragment analog; nootropic Modified Semax analog (nootropic)
Drug class Cognitive Cognitive
Mechanism Upregulates BDNF and NGF; modulates dopamine and serotonin systems; neuroprotective Similar to Semax; BDNF/NGF upregulation; enhanced stability
Route Intranasal / SC Intranasal
Half-life ~5-15 min (intranasal peak) ~minutes
Dosage (research) 200 mcg intranasal daily (0.1% solution, 2-3 drops per nostril, nootropic starting dose, max 600 mcg/day per Russian clinical literature for stroke and cognitive support) 200-600 mcg intranasal daily
Evidence tier Russia-Approved + Anecdotal Anecdotal
Research depth 150 indexed (PubMed 141 · CT 0 · EPMC 9) 6 indexed (PubMed 6 · CT 0 · EPMC 0)
Availability Research / Intl Rx Research Chemical
Reported risks Mild irritability; insomnia; nasal irritation with intranasal use Very limited human data

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Semax or Adamax?

Semax has stronger documented evidence (Russia-Approved + Anecdotal) than Adamax (Anecdotal) while both occupy the nootropic / bdnf-upregulator classes. When clinical-evidence tier is the deciding factor, Semax is the safer pick. Adamax may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between Semax and Adamax?

Semax is classed as ACTH fragment analog; nootropic; Adamax is classed as Modified Semax analog (nootropic). Reported mechanism: Semax, Upregulates BDNF and NGF; modulates dopamine and serotonin systems; neuroprotective; Adamax, Similar to Semax; BDNF/NGF upregulation; enhanced stability. Reported half-life: Semax, ~5-15 min (intranasal peak); Adamax, ~minutes. Routes in published studies: Semax, Intranasal / SC; Adamax, Intranasal.

Which has stronger evidence, Semax or Adamax?

Semax has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Semax is graded Russia-Approved + Anecdotal, with 5 cited sources on its reference page and 150 indexed studies. Adamax is graded Anecdotal, with 6 cited sources on its reference page and 6 indexed studies.

Which is more accessible, Semax or Adamax?

Neither Semax nor Adamax is an FDA-approved drug. Catalog status: Semax, Research / Intl Rx; Adamax, Research Chemical. Semax's nomination for FDA's bulk-substance lists was flagged by FDA and then withdrawn.

Are Semax and Adamax ever combined?

Semax and Adamax appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…